Annals of oncology : official journal of the European Society for Medical Oncology · 2026
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aldea M, Lenahan S M, Locquet M-A, Liao L, Gasparro M, Gokhale P C, Ghigna M-R, Ionescu D N, Odintsov I, Ngo K, Wang X, Aziz S, Pecci F, Garbo E, Ivanova E, Nakazawa S, Kulesza J, Tsai J A, Zullo L, Lee J, Zielinska M, Simon S, Han D, Marinello A, Li G, Rossato de Almeida G, Huang J, Paoloni F, Gariazzo E, Santo V, Remon J, Marks J A, LoPiccolo J, Florez N, Nishino M, Ricciuti B, Luo J, Barbie D A, Planchard D, Rotow J K, Barlesi F, Graf R P, Feng W W, Besse B, Paweletz C, Sholl L, Shaw A T, Jänne P A
Аннотация
BACKGROUND: Homozygous loss of methylthioadenosine phosphorylase (MTAP) occurs in ∼15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability to PRMT5 inhibitors. The frequency and therapeutic relevance of MTAP loss in oncogene-driven non-small-cell lung cancers (NSCLCs) remain underexplored.
METHODS: MTAP status was assessed by next-generation sequencing (NGS) or immunohistochemistry (IHC) in >13 000 NSCLC samples in four cohorts. Prevalence was assessed across oncogenic drivers and temporal dynamics in pre- and post-treatment biopsies. Clinical outcomes were analyzed in EGFR- and ALK-rearranged NSCLC treated with first-line osimertinib and alectinib, respectively. The methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor BMS-986504 was tested alone and in combination with targeted therapies (TT) in MTAP-deleted models in vitro, ex vivo, and in vivo.
RESULTS: MTAP loss was frequent in ALK-rearranged (27% and 33% by NGS; 36% and 45% IHC), RET-rearranged (18.5% and 26% by NGS; 35% by IHC), and EGFR-mutant NSCLC (17% and 24% by NGS; 24% and 29% by IHC), with CDKN2A co-deletion in 98% of cases. MTAP loss was typically present before TT. MTAP loss did not significantly impact response or overall survival with first-line osimertinib or alectinib in EGFR-mutant and ALK-rearranged NSCLC, respectively. In preclinical studies, BMS-986504 showed nanomolar activity in 11/18 MTAP-deleted models, including 5/8 EGFR- and 5/5 ALK-driven models, regardless of TT sensitivity. Synergistic or additive effects with TT were observed in 11/18 models. In ex vivo ALK-rearranged spheroids resistant to crizotinib, the combination of BMS-986504 and alectinib improved antitumor activity over monotherapy. In an osimertinib-resistant, EGFR-mutant patient-derived xenograft model, BMS-986504 with or without osimertinib controlled tumor growth, without weight loss.
CONCLUSIONS: MTAP loss is frequent in oncogene-driven NSCLC, particularly in ALK-, RET-, and EGFR-altered subtypes. MTA-cooperative PRMT5 inhibition demonstrates broad activity in MTAP-deleted, oncogene-driven models and, and may enhance targeted therapy efficacy in selected settings.
METHODS: MTAP status was assessed by next-generation sequencing (NGS) or immunohistochemistry (IHC) in >13 000 NSCLC samples in four cohorts. Prevalence was assessed across oncogenic drivers and temporal dynamics in pre- and post-treatment biopsies. Clinical outcomes were analyzed in EGFR- and ALK-rearranged NSCLC treated with first-line osimertinib and alectinib, respectively. The methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor BMS-986504 was tested alone and in combination with targeted therapies (TT) in MTAP-deleted models in vitro, ex vivo, and in vivo.
RESULTS: MTAP loss was frequent in ALK-rearranged (27% and 33% by NGS; 36% and 45% IHC), RET-rearranged (18.5% and 26% by NGS; 35% by IHC), and EGFR-mutant NSCLC (17% and 24% by NGS; 24% and 29% by IHC), with CDKN2A co-deletion in 98% of cases. MTAP loss was typically present before TT. MTAP loss did not significantly impact response or overall survival with first-line osimertinib or alectinib in EGFR-mutant and ALK-rearranged NSCLC, respectively. In preclinical studies, BMS-986504 showed nanomolar activity in 11/18 MTAP-deleted models, including 5/8 EGFR- and 5/5 ALK-driven models, regardless of TT sensitivity. Synergistic or additive effects with TT were observed in 11/18 models. In ex vivo ALK-rearranged spheroids resistant to crizotinib, the combination of BMS-986504 and alectinib improved antitumor activity over monotherapy. In an osimertinib-resistant, EGFR-mutant patient-derived xenograft model, BMS-986504 with or without osimertinib controlled tumor growth, without weight loss.
CONCLUSIONS: MTAP loss is frequent in oncogene-driven NSCLC, particularly in ALK-, RET-, and EGFR-altered subtypes. MTA-cooperative PRMT5 inhibition demonstrates broad activity in MTAP-deleted, oncogene-driven models and, and may enhance targeted therapy efficacy in selected settings.
Предметные рубрики MeSH
HumansCarcinoma, Non-Small-Cell LungProtein-Arginine N-MethyltransferasesLung NeoplasmsPurine-Nucleoside PhosphorylaseAnimalsFemalePyrimidinesIndolesMiceAcrylamidesXenograft Model Antitumor AssaysMaleAniline CompoundsCell Line, TumorErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsMolecular Targeted Therapy